查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434657

自体免疫疾病治疗药物市场：按适应症、药物类别、分布划分 - 全球预测 2024-2030

Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年自体自体免疫疾病治疗市场规模为1,087.1亿美元，预计2024年将达1,167.9亿美元，复合年增长率为7.52%，2030年将达1,806.7亿美元。

自体免疫疾病药物的全球市场

主要市场统计
基准年[2023] 1087.1亿美元
预测年份 [2024] 1167.9亿美元
预测年份 [2030] 1806.7亿美元
复合年增长率（%） 7.52%
自体免疫疾病治疗市场-IMG1

FPNV定位矩阵

FPNV 定位矩阵对于评估自体免疫疾病治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对自体自体免疫疾病治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-自体免疫疾病治疗药物市场的市场规模和预测是多少？

2-在自体自体免疫疾病治疗药物市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-自体免疫疾病治疗药物市场的技术趋势和法律规范是什么？

4-自体自体免疫疾病治疗药物市场主要供应商的市场占有率是多少？

5-进入自体免疫疾病药物市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫疾病发生率增加类风湿性关节炎、墓碑病、桥本氏甲状腺病
      • 人们对自体免疫疾病的认识不断增强
      • 完善政府援助、资助和报销政策
    • 抑制因素
      • 与自体免疫疾病药物相关的副作用
    • 机会
      • 后期管道药物的进展和可用性
      • 自体自体免疫疾病治疗的持续研究与创新
    • 任务
      • 治疗自体免疫疾病的药物变得越来越昂贵。
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章自体免疫疾病治疗药物市场（按适应症）

  • 1型糖尿病
  • 多发性硬化症
  • 罕见疾病
  • 风湿性疾病

第七章依药物类别分類的自体自体免疫疾病治疗药物市场

  • 发炎
  • 降血糖药
  • 免疫抑制剂
  • 干扰素
  • 非类固醇消炎剂

第八章自体自体免疫疾病治疗药物市场分布

  • 医院药房
  • 网路商店
  • 零售药房

第九章北美和南美自体免疫疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区自体免疫疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲自体自体免疫疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：按主要企业划分
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AESKU.GROUP GmbH & Co. KG
    • AstraZeneca PLC
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories, Inc.
    • BioAgilytix Labs, LLC
    • Biogenuix Medsystems Private Limited
    • bioMerieux SA
    • Exagen, Inc.
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi SA
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • Werfen SA
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-436901065FF2

[191 Pages Report] The Autoimmune Disease Drugs Market size was estimated at USD 108.71 billion in 2023 and expected to reach USD 116.79 billion in 2024, at a CAGR 7.52% to reach USD 180.67 billion by 2030.

Global Autoimmune Disease Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 108.71 billion
Estimated Year [2024] USD 116.79 billion
Forecast Year [2030] USD 180.67 billion
CAGR (%) 7.52%
Autoimmune Disease Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autoimmune Disease Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autoimmune Disease Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMerieux S.A., Exagen, Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Diabetes Mellitus Type 1
    • Multiple Sclerosis
    • Rare Diseases
    • Rheumatic Diseases
  • Drug Class
    • Anti-Inflammatory
    • Antihyperglycemic
    • Immunosuppressants
    • Interferons
    • Nonsteroidal Anti-Inflammatory Drugs
  • Distribution
    • Hospital Pharmacies
    • Online Stores
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autoimmune Disease Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autoimmune Disease Drugs Market?

3. What are the technology trends and regulatory frameworks in the Autoimmune Disease Drugs Market?

4. What is the market share of the leading vendors in the Autoimmune Disease Drugs Market?

5. Which modes and strategic moves are suitable for entering the Autoimmune Disease Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Autoimmune Disease Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
      • 5.1.1.2. Growing awareness of autoimmune diseases
      • 5.1.1.3. Improved government assistance, funding, and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects of autoimmune disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and availability of late-stage pipeline drugs
      • 5.1.3.2. Ongoing research and innovations in autoimmune disease drugs
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of autoimmune disease medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Autoimmune Disease Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Diabetes Mellitus Type 1
  • 6.3. Multiple Sclerosis
  • 6.4. Rare Diseases
  • 6.5. Rheumatic Diseases

7. Autoimmune Disease Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Antihyperglycemic
  • 7.4. Immunosuppressants
  • 7.5. Interferons
  • 7.6. Nonsteroidal Anti-Inflammatory Drugs

8. Autoimmune Disease Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Stores
  • 8.4. Retail Pharmacies

9. Americas Autoimmune Disease Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autoimmune Disease Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autoimmune Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AESKU.GROUP GmbH & Co. KG
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Beckman Coulter, Inc.
    • 13.1.5. Bio-Rad Laboratories, Inc.
    • 13.1.6. BioAgilytix Labs, LLC
    • 13.1.7. Biogenuix Medsystems Private Limited
    • 13.1.8. bioMerieux S.A.
    • 13.1.9. Exagen, Inc.
    • 13.1.10. F. Hoffmann-La Roche AG
    • 13.1.11. Novartis AG
    • 13.1.12. Pfizer, Inc.
    • 13.1.13. Sanofi S.A.
    • 13.1.14. Siemens Healthineers AG
    • 13.1.15. Thermo Fisher Scientific Inc.
    • 13.1.16. Trinity Biotech PLC
    • 13.1.17. Werfen S.A.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AUTOIMMUNE DISEASE DRUGS MARKET DYNAMICS
  • FIGURE 7. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 12. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTIHYPERGLYCEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. AUTOIMMUNE DISEASE DRUGS MARKET LICENSE & PRICING